Completed PHASE3 INTERVENTIONAL 2-arm NCT00082433

Epothilone (Ixabepilone) Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer

A Phase III Study of Novel Epothilone (Ixabepilone) Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer Previously Treated With an Anthracycline and a Taxane

Sponsor: R-Pharm

Conditions Breast Cancer Cancer

Interventions Capecitabine Ixabepilone + Capecitabine

Updated 8 times since 2017 Last updated: Oct 6, 2020 Started: Nov 30, 2003 Primary completion: Mar 31, 2008 Completion: Mar 31, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00082433, this PHASE3 trial focuses on Breast Cancer and Cancer and remains completed. Sponsored by R-Pharm, it has been updated 8 times since 2003, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Dec 2020 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 3 earlier versions

Jun 2018 — Dec 2020 [monthly]

Completed PHASE3
Feb 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Nov 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

R-Pharm

Data source: R-Pharm

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aalborg, Denmark , Adelaide, Australia , Albuquerque, United States , Angers, France , Ankara, Turkey (Türkiye) , Arnhem, Netherlands , Athens, Greece , Avellaneda, Argentina , Bahía Blanca, Argentina , Barcelona, Spain and 176 more locations